A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19

INTRODUCTION: Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swept rapidly throughout the world. So far, no therapeutics have yet proven to be effective. Ribavirin was recommended for the treatment of COVID-19 in China because of its in vit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Wei-Jing, Zhou, Tao, Wu, San-Lan, Ye, Jia-Long, Xu, Jia-Qiang, Zeng, Fang, Su, Yu-Yong, Han, Yong, Lv, Yong-Ning, Zhang, Yu, Cai, Xue-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894089/
https://www.ncbi.nlm.nih.gov/pubmed/33676844
http://dx.doi.org/10.1016/j.jiac.2021.02.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894089/
https://www.ncbi.nlm.nih.gov/pubmed/33676844
http://dx.doi.org/10.1016/j.jiac.2021.02.018

Ejemplares similares